TMO Thermo Fisher Scientific
Toll-collector on biopharma R&D and manufacturing; fair value depends on organic reinvestment efficiency, not headline M&A.
The story
Thermo Fisher is the scale leader in life sciences tools, bioproduction and CRO/CDMO services. A consumables-heavy, spec-locked installed base and one-stop-shop breadth give it a durable moat. After the post-COVID normalization and a flat 2022-2024, it is a mature compounder returning to mid-single-digit organic growth, helped by biologics and pharma outsourcing, while academic/government and China demand stay soft.
GAAP margin of 19.6% is weighed down by roughly 3 points of acquired-intangible amortization, so a 23.5% target reflects cash operating economics rather than a peak. The historical 0.5 sales-to-capital is inflated by acquisition goodwill; organic incremental reinvestment runs much higher, so 1.6 is used, and that difference is the main reason for the gap to the baseline's $181. The 12-year horizon fits a franchise with a long bioprocessing and outsourcing runway, and terminal growth of 3.5% stays below the 5.11% risk-free rate.
Value drivers
| Revenue growth (Y1) | 5.0% |
| Terminal growth | 3.5% |
| Forecast horizon | 12y |
| Target operating margin | 23.5% |
| Years to target margin | 5 |
| Sales-to-capital | 1.60 |
| Beta | 0.95 |
| Failure probability | 1.0% |
| Cost of capital (WACC) | 9.1% |
| Terminal WACC | 9.3% |
Valuation bridge
| PV of explicit FCFF | 78.60B |
| PV of terminal value | 65.50B |
| Equity value | 113.29B |
| ÷ shares → per share | $306.40 |
News
neutral -0.10 · 8 articles
- Thermo Fisher Scientific (TMO) Rolls Out New Media Panel For Biologics Development
- G2’s CFO says SaaS expos may become obsolete
- 3 Reasons to Sell TMO and 1 Stock to Buy Instead
- Beat the Market Like Zacks: PBF, Palantir, Adobe in Focus
- Mayo Clinic, Thermo Fisher partner to create Precure
- Jim Cramer Said These 2 Stocks Were Sold Because Of A Rotation – But Is He Right?
- Thermo Fisher Scientific (TMO) is Positioned for Resurgence
- Three Analysts, Three Verdicts on Thermo Fisher: Here’s Who the Numbers Favor
Projected free cash flow to the firm
| Yr | Revenue | Growth | Margin | NOPAT | Reinvest | FCFF | PV |
|---|---|---|---|---|---|---|---|
| 1 | 48.65B | 5.0% | 20.4% | 9.19B | 1.45B | 7.74B | 7.10B |
| 2 | 51.02B | 4.9% | 21.2% | 10.00B | 1.48B | 8.52B | 7.16B |
| 3 | 53.43B | 4.7% | 22.0% | 10.85B | 1.51B | 9.35B | 7.21B |
| 4 | 55.88B | 4.6% | 22.7% | 11.75B | 1.53B | 10.22B | 7.22B |
| 5 | 58.37B | 4.5% | 23.5% | 12.69B | 1.56B | 11.14B | 7.22B |
| 6 | 60.89B | 4.3% | 23.5% | 13.24B | 1.58B | 11.66B | 6.93B |
| 7 | 63.44B | 4.2% | 23.5% | 13.79B | 1.59B | 12.20B | 6.65B |
| 8 | 66.01B | 4.0% | 23.5% | 14.35B | 1.60B | 12.75B | 6.37B |
| 9 | 68.59B | 3.9% | 23.5% | 14.91B | 1.61B | 13.30B | 6.09B |
| 10 | 71.17B | 3.8% | 23.5% | 15.47B | 1.62B | 13.86B | 5.82B |
| 11 | 73.76B | 3.6% | 23.5% | 16.04B | 1.62B | 14.42B | 5.55B |
| 12 | 76.34B | 3.5% | 23.5% | 16.60B | 1.61B | 14.98B | 5.29B |
Key risks
- Prolonged weakness in biotech funding and NIH/academic budgets
- China demand, tariffs and Biosecure-related supply-chain disruption
- Overpaying for acquisitions: serial M&A dilutes returns on capital and adds leverage
Catalysts
- Bioproduction destocking ends and GLP-1/biologics capacity build-out drives consumables volumes
- Pharma onshoring and outsourcing lift CDMO/clinical research bookings